Patients with organ or islet transplants live with the life-long possibility of rejection, whereas recipients of HCT face the reverse problem: GVHD (where newly-transplanted immune system attacks the body). The immunosuppressive medications that keep rejection and chronic GVHD at bay do so by suppressing all immune responses, leaving patients at high risk of cardiovascular disease, diabetes, hypertension, renal toxicity and cancer. Patients have identified the inadequacy of current medications and their toxic side-effects as a top research priority.

Patients with organ or islet transplants live with the life-long possibility of rejection, whereas recipients of HCT face the reverse problem: GVHD (where newly-transplanted immune system attacks the body). The immunosuppressive medications that keep rejection and chronic GVHD at bay do so by suppressing all immune responses, leaving patients at high risk of cardiovascular disease, diabetes, hypertension, renal toxicity and cancer. Patients have identified the inadequacy of current medications and their toxic side-effects as a top research priority.

Focal Points

  • Immunomodulation strategies

  • Infections and Immunity

Join the Theme
Request Research Support
0
Projects

Examples of Projects in Theme 4 include

  • Thymic Treg Therapy

  • Immunemonitoring

  • HLA Technologies

  • ABO/ABH Technology

Theme Leaders

Megan Levings
Megan LevingsAcademic Lead
Atul Humar
Atul HumarAcademic Co-Lead
Elaine Yong
Elaine YongPatient Co-Lead

Theme Manager
Dr. Leanne Stalker